NCT02639026 2025-11-25
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
Clinical Trials
7 trialsNCT05928962 2023-07-10
An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas
Fujian Cancer Hospital
Phase 1 Unknown
NCT01103635 2020-04-07
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT04274816 2020-02-18
Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma
Amsterdam UMC, location VUmc
Phase 1 Completed
NCT02586987 2019-11-18
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00431275 2012-06-06
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody
AstraZeneca
Phase 1 Completed
NCT00585000 2012-06-06
A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma
AstraZeneca
Phase 1 Terminated